A groundbreaking new venture, ENDSULIN, is unlocking new gene therapy techniques to free diabetic patients from the daily burdens of today’s taxing treatments.
Dr. Hans Sollinger has invented a patented DNA sequence (called GIRE) that can help the body regulate insulin on its own. Now, their team is working to develop the discovery into a durable treatment that could regulate glycemic control for millions of patients, without daily injections and management.
This advancement could revolutionize the way we treat diabetes.
The GIRE reprograms a fraction of the hepatocytes in the liver to regulate insulin release precisely depending on blood glucose levels. The results could be long-lasting euglycemia control.
The research is promising, and ENDSULIN is conducting the first-ever pilot study in large, naturally diabetic dogs.